Clinical Hematology & Oncology: 2021


Basic Clinical Concepts in Thrombosis Diagnosis and Management: Refresher and 22 Teaching Points

Stephan Moll, MD, presents the basic concepts of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE); looking at medical history, diagnostic testing, and treatment options for patients.
Stephan Moll, MD

Stephan Moll, MD

Professor of Medicine
Department of Hematology-Oncology
University of North Carolina School of Medicine

HIT Clinical “Pearls”

Dr. Ted Warkentin describes the pathophysiology and clinical presentation of Heparin-induced thrombocytopenia (HIT) and explains the potential complications, and treatment options.
Theodore (Ted) Warkentin, MD, BSc

Theodore (Ted) Warkentin, MD, BSc

Professor, Pathology and Molecular Medicine
Division of Hematology (Transfusion Medicine)
McMaster University

Sickle Cell Disease and Hemoglobinopathies: 2021 Update for the Practicing Heme-Onc Healthcare Professional

Dr. Jane Little identifies hemoglobinopathies and presents on Sickle cell disease (SCD) as one such blood disorder caused by the abnormal hemoglobin that damages and deforms red blood cells.
Jane Little, MD

Jane Little, MD

Professor of Medicine, Division of Hematology and Oncology
Director, UNC Comprehensive Sickle Cell Disease Program
University of North Carolina School of Medicine

The Most Relevant Clinical Bleeding Developments of the Last 12 Months

Alice Ma, MD, discusses Acquired Hemophilia and Hemophilia, explains ITP, and also provides an update on Von Willebrand Disease.
Alice Ma, MD

Alice Ma, MD

Professor of Medicine
The Medical Alumni Loyalty Fund Distinguished Teaching Professor
University of North Carolina School of Medicine

Hematologic Aspects of COVID-19

Thomas Lee Ortel, MD, PhD, explains Hematologic manifestations, Prothrombotic mechanisms, and Antithrombotic therapy for patients with COVID-19.
Thomas Ortel, MD, PhD

Thomas Ortel, MD, PhD

Professor of Medicine & Pathology; Chief, Division of Hematology
Medical Director, Coagulation and Platelet Antibody Laboratories
Duke University School of Medicine

Hematological Problems of Pregnancy

John Kelton, MD identifies anemia secondary to iron deficiency as the most frequent hematologic complication during pregnacy and explains treatment options.
John Kelton, MD

John Kelton, MD

Professor, Pathology and Molecular Medicine
Executive Director, Michael G. DeGroote Initiative for Innovation in Healthcare
McMaster University

Tailoring Maintenance Therapy of Myeloma

Morie A. Gertz, MD provides considerations on tailoring maintenance for patients with Myeloma and provides drug recommendations and treatments.
Morie Gertz, MD

Morie Gertz, MD

Consultant, Division of Hematology
Roland Seidler Jr. Professor Department of Medicine
Mayo Clinic

Diffuse Large Cell Lymphoma Subtypes and Treatment

Andrew D. Zelenetz, MD, PhD, identifies the classification of lymphoma and recalls standard of care.
Andrew Zelenetz, MD, PsyD

Andrew Zelenetz, MD, PsyD

Medical Oncologist
Medical Director, Quality Informatics
Memorial Sloan Kettering Cancer Center

Treatment Approaches to Mantle Cell Lymphoma

Luhua (Michael) Wang, MD, reviews Mantle Cell Lymphoma therapy options, and recalls patient responses and outcomes to treatment.
Luhua (Michael) Wang, MD

Luhua (Michael) Wang, MD

Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center

Modern Treatment Options for CLL

Dr. Anthony Mato explains novel therapeutics in Chronic Lymphocytic Leukemia (CLL).
Anthony Mato, MD, MSCE

Anthony Mato, MD, MSCE

Director, CLL Program
Hematologic Oncologist
Memorial Sloan Kettering Cancer Center

AML in the Older Population

Hagop M. Kantarjian, MD reviews the latest updates on Acute myeloid leukemia (AML) in the older population, and explains it is the most common type of acute leukemia in adults.
Hagop Kantarjian, MD

Hagop Kantarjian, MD

Professor and Chairman, Department of Leukemia
Samsung Distinguished University Chair in Cancer Medicine
The University of Texas MD Anderson Cancer Center

Therapeutic Updates for Follicular and Marginal Zone Lymphoma

Loretta J. Nastoupil, MD, reviews prognostic biomarkers to advance the timely identification and risk assessment of patients with follicular lymphoma (FL) for prompt treatment and/or referrals.
Loretta Nastoupil, MD

Loretta Nastoupil, MD

Associate Professor
Department of Lymphoma/Myeloma, Division of Cancer Medicine
Section Chief, Indolent Lymphoma; Section Chief, New Drug Development
The University of Texas MD Anderson Cancer Center

The Race Toward Equity: Increasing Racial Diversity in Cancer Research and Cancer Care

Lori J. Pierce, MD presents on racial diversity in cancer research and cancer care and outlines social and health inequities in the U.S.
Lori Pierce, MD

Lori Pierce, MD

ASCO President
Vice Provost for Academic and Faculty Affairs,
Professor of Radiation Oncology
University of Michigan

The Evolving Paradigm of Melanoma Treatment

Janice Mehnert, MD, reviews recent developments in Melanoma treatments, specifically Adjuvant and Neoadjuvant landscapes. Dr. Mehnert identifies a selection of targeted therapys versus immunotherapy, and also describes the management of brain metastases.
Janice Mehnert, MD

Janice Mehnert, MD

Associate Director, Clinical Research
Laura and Isaac Perlmutter Cancer Center at NYU
Disease Management Group Leader
Melanoma and Cutaneous Oncology NYU Langone Health

Immunotherapy and Targeted Therapy in Upper GI Cancers

Sam Klempner, MD, addresses what has changed in immunotherapy and targeted therapy in upper GI cancers, and reviews barriers that are preventing improvement.
Sam Klempner, MD

Sam Klempner, MD

GI Oncology
MGH Cancer Center
Massachusetts General Hospital

How to Prioritize the Many Therapeutic Options for HER2+ Metastatic Breast Cancer

Debasish Tripathy, MD identifies the latest therapeutic options for HER2+ metastatic breast cancer and provides treatments for the advanced disease.
Debasish Tripathy, MD

Debasish Tripathy, MD

Professor and Chair, Department of Breast Medical Oncology
MD Anderson Cancer Center, University of Texas

Management of Non-Clear Cell RCC

Sumanta Kumar Pal, MD reviews the distribution of kidney cancers and explains clinical management of non-clear cell Renal Cell Carcinoma (RCC), with a focus on Papillary RCC.
Sumanta Kumar Pal, MD

Sumanta Kumar Pal, MD

Clinical Professor, Department of Medical Oncology & Therapeutics Research
Co-director, Kidney Cancer Program
City of Hope

Updates in NSCLC with Emphasis on Front Line Therapy

Suresh S. Ramalingam, MD explains Non-small Cell Lung Cancer (NSCLC), and identifies therapy for patients with driver mutations such as EGFR, ALK, and RET. Dr. Ramalingam also presents immunotherapy options for patients without driver ...
Suresh Ramalingam, MD

Suresh Ramalingam, MD

Professor of Hematology and Medical Oncology, Roberto C. Goizueta Chair for Cancer Research Director, Division of Medical Oncology; Deputy Director, Winship Cancer Institute
Emory Winship Cancer Institute

Targeted Approaches in Sarcoma

Arun S. Singh, MD, provides the history of sarcoma management and reviews the latest updates in treatment of targeted therapy.
Arun Singh, MD

Arun Singh, MD

Medicine, Hematology and Oncology
University of California, Los Angeles Health

Optimizing Immunotherapy for Metastatic Breast Cancer

Heather L. McArthur, MD, MPH presents a case study using immunotherapy to treat Metastatic Breast Cancer. Dr. McArthur also reviews clinical trials and discusses future treatment options.
Heather McArthur, MD, MPH

Heather McArthur, MD, MPH

Medical Director, Breast Oncology
Cedars Sinai Medical Center

Practical Aspects of Novel Imaging Approaches in the Management of Prostate Cancer

Jeremie Calais, MD, MSc, reviews PET molecular imaging of prostate cancer, and describes Prostate Specific Membrane Antigen (PSMA).
Jeremie Calais, MD, MSc, BA

Jeremie Calais, MD, MSc, BA

Assistant Professor, Nuclear Medicine and Theranostics
Director, Clinical Research Program
University of California, Los Angeles

Update on Systemic Therapies for Thyroid Cancer

Eric J. Sherman, MD, provides an update on the different subtypes and therapies for thyroid cancer.
Eric Sherman, MD

Eric Sherman, MD

Medical Oncologist, Head and Neck Cancer; Thyroid Cancer
Memorial Sloan Kettering Cancer Center

New Approaches to Recurrent or Advanced Bladder Cancer

Dean F. Bajorin, MD, presents urothelial cancer, and reviews the expected survival rates for bladder cancer patients who receive first line treatment, and discusses new treatment options.
Dean Bajorin, MD

Dean Bajorin, MD

Medical Oncologist
Frederick R. Adler Senior Faculty Chair
Memorial Sloan Kettering Cancer Center

The Evolving Role of Liquid Biopsies

David R. Gandara, MD, FASCO, discusses the evolving role of liquid biopsy in therapeutic decision-making for Non-small Cell Lung Cancer (NSCLC).
David Gandara, MD, FASCO

David Gandara, MD, FASCO

Professor of Medicine Emeritus
Director, Thoracic Oncology Program
University of California Davis Comprehensive Cancer

Return to Main Menu »

Course Overview

The 2021 Clinical Hematology and Oncology conference is designed for hematologists, oncologists, surgeons, radiation oncologists, internists, and others desiring an update in these specialty areas. The primary objective of this course is to bring together clinicians and leading experts affording them an intimate learning environment in which to discuss new clinical developments and significant advances in diverse areas of hematology and oncology.

Educational Objectives

  • Describe the clinical and molecular facets of pathogenesis, diagnostic approaches, and therapeutic modalities available for various hematologic disorders.
  • Select and apply the changing approaches to hematologic malignancies, particularly as they relate to evidence-based standards of care, including innovations in diagnosis and treatment.
  • Choose new therapeutic options for the treatment of several common malignancies, understanding appropriate indications and contraindications to these therapeutic approaches.
  • Integrate evolving approaches to solid tumors and breast cancer from both a diagnostic, prognostic, and therapeutic perspective.
  • Apply practical expertise gained from the clinical situations discussed in the panel sessions with an emphasis on data-based approaches to patients with common, but serious hematology oncology conditions.

Target Audience

  • Hematologists/Oncologists
  • Medical Oncologists
  • Surgeons
  • Radiation Oncologists
  • Internists
  • And others desiring an update in these specialty areas

View Faculty Disclosures »